ADVANCED NON-SMALL CELL LUNG CANCER

This study tests whether adding local treatments (like radiation or surgery) to the targeted drug lorlatinib can better control ALK-positive advanced non-small cell lung cancer. About 30 people who have not had prior targeted therapy will take lorlatinib for 12 weeks, then may re…

This study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) in people with advanced lung cancer that has specific uncommon genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease…

This study tests a new drug combination (JSKN016 plus other treatments) in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. About 288 adults aged 18–75 will take part. The goal is to see if the combination shrinks tumors and to che…

This study tests a new daily pill, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 adults will take either the pill or standard treatment. The goal is to see if the pill delays…

This study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…

This study tests a new drug, SHR-A1811, combined with either pyrotinib or SHR-1316 in people with advanced HER2-positive non-small cell lung cancer. The goal is to see if these combinations are safe and can shrink tumors. About 324 adults aged 18-75 with good performance status a…

This early-phase study tests whether adding two inhaled antibiotics (aztreonam and vancomycin) to the standard cancer drug pembrolizumab can help control advanced non-small cell lung cancer. About 23 adults whose cancer has returned or spread will receive the combination over six…

This program offers an experimental oral medication, sevabertinib, to adults with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has stopped responding to other treatments. Participants must have a life expectancy of at least 12 weeks and be in rel…

This study tests a treatment that uses your own immune cells taken from your tumor, grown in a lab, and given back to you to fight advanced non-small cell lung cancer. The goal is to see if these cells can shrink tumors and if the treatment is safe. Participants must be 18-72 and…

This study compares the targeted drug tepotinib to standard treatments in 133 people with advanced MET-mutated non-small cell lung cancer whose disease has worsened after initial therapy. Tepotinib is a pill that blocks cancer growth and has shown a 50% response rate in earlier s…

This early-phase study tests an experimental drug called PF-08046876 in adults with advanced solid tumors (bladder, lung, head/neck, esophagus, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to stick to cancer…

This study tests whether a new experimental drug (PF-08634404) combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer that has spread. About 1,410 participants will be randomly ass…

This study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …